EyeGate Pharma Completes Phase II Study Of EGP-437 In Patients With Anterior
0 Comments |
Share |
33 Views |
Problem? |
10/17/09
Linked From Medical News Today
:
EyeGate Pharma, the leader in non-invasive ocular drug delivery, announces the completion of a Phase II study of its lead product candidate, EGP-437,